



287.1006

UNITED STATES PATENT AND TRADEMARK OFFICE

Re: Application of: Ralph A. HEASLEY, et al.
Serial No.: 10/631,371
Filed: July 31, 2003
Examiner: Blessing M. FUBARA
For: **TRANEXAMIC ACID FORMULATIONS
WITH REDUCED ADVERSE EFFECT**
Art Unit: 1618

Mail Stop: Amendment March 13, 2007
Commissioner for Patents
P.O. Box 1450
Alexandria, VA, 22313-1450

**SUPPLEMENTAL INFORMATION DISCLOSURE
STATEMENT UNDER 37 C.F.R. 1.56**

Sir:

In accordance with Applicant's duty of disclosure under 37 C.F.R. § 1.56 and the provisions of 37 C.F.R. §§ 1.97 and 1.98, Applicants hereby make of record the references listed on the accompanying Form PTO-1449 (1 sheet) for consideration by the Examiner in connection with the examination of the above-identified patent application.

In accordance with 37 C.F.R. § 1.98(a)(2), copies of the publications are enclosed.

Pursuant to the waiver of the requirement under 37 C.F.R. § 1.98(a)(2)(i) for submitting a copy of each cited U.S. patent and each U.S. patent application publication for all U.S. national patent applications filed after June 30, 2003, copies of the cited U.S. patents and U.S. patent application publications are not enclosed. If it is determined that any of the listed references are not presently enclosed, the Examiner is requested to contact the undersigned so that a copy can be forwarded.

Applicants note that References “AA” and “AB” cited on the accompanying PTO-1449 form were cited in a Written Opinion of the International Searching Authority in the corresponding application PCT/US2005/020563. Applicants note that References “AA” cited on the accompanying PTO-1449 form was cited in a Written Opinion of the International Searching Authority in the corresponding application PCT/US05/20558.

Applicants also respectfully advise the Examiner of the following co-pending U.S. Patent Applications which are commonly assigned to the owners of the instant application:

U.S. Application Serial No. 11/072,194, entitled “Tranexamic Acid Formulations”, filed March 4, 2005, published on November 03, 2005 as US-2005-0244495-A1; and

U.S. Application Serial No. 11/072,162, entitled “Tranexamic Acid Formulations”, filed March 4, 2005, published on November 03, 2005 as US-2005-0245614-A1; and

U.S. Application Serial No. 11/346,710, entitled “Tranexamic Acid Formulations With Reduced Adverse Effects”, filed February 3, 2006, published on June 15, 2006 as US-2006-0127476-A1.


It is respectfully requested that the references cited on the accompanying Form PTO-1449 (1 sheet) be considered and made of record.

This Information Disclosure Statement is being filed under 37 C.F.R. §1.97 (c)(2). A check in the amount of \$180.00 is enclosed for the fee due under 37 C.F.R. § 1.17 (p). It is believed that no additional fee is due. In the event any additional fee is due in connection with this response or if any fee has been overpaid, the deficiency or overpayment should be charged to our Deposit Account No. 50-0552.

Respectfully submitted,

DAVIDSON, DAVIDSON & KAPPEL, LLC

By _____



Richard V. Zanzalari
Reg. No. 49,032

Davidson, Davidson & Kappel, LLC
485 Seventh Avenue, 14th Floor
New York, New York 10018
(212) 736-1940

| FORM PTO-1449 (REV. 7-80) | | U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE | | ATTY. DOCKET NO.: 287.1006 | SERIAL NO.: 10/631,371 | | | |
|---|----|--|--|---|---------------------------|-------|----------|----------------------------|
| LIST OF PRIOR ART CITED BY APPLICANT | | | | APPLICANT(S): Ralph A. HEASLEY, et al. | | | | |
| (Use several sheets if necessary) | | MAR 16 2007 U.S. PATENT & TRADEMARK OFFICE | | FILING DATE: July 31, 2003 | GROUP: 1618 | | | |
| PATENT DOCUMENTS | | | | | | | | |
| *EXAMINER INITIAL | | DOCUMENT NUMBER | | DATE | NAME | CLASS | SUBCLASS | FILING DATE IF APPROPRIATE |
| | AA | 5 5 0 6 2 6 4 | | 04/09/1996 | Fujimura, et al. | 514 | 494 | |
| | AB | 4 4 6 5 6 6 2 | | 08/14/1984 | Sato, et al. | 424 | 54 | |
| | AC | | | | | | | |
| | AD | | | | | | | |
| | AE | | | | | | | |
| | AF | | | | | | | |
| | AG | | | | | | | |
| FOREIGN PATENT DOCUMENTS | | | | | | | | |
| | | DOCUMENT NUMBER | | DATE | COUNTRY | CLASS | SUBCLASS | TRANSLATION |
| | AH | | | | | | | YES |
| | AI | | | | | | | NO |
| | AJ | | | | | | | |
| | AK | | | | | | | |
| | AL | | | | | | | |
| OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.) | | | | | | | | |
| | AM | Cooper, K. G., et al., "A randomised comparison of medical and hysteroscopic management in women consulting a gynaecologist for treatment of heavy menstrual loss." Br. J. Obstet. Gynaecol vol. 104, pgs 1360-1366 (1997). | | | | | | |
| | AN | Cooper, K. G., et al., "Two-year follow up of women randomised to medical management or transcervical resection of the endometrium for heavy menstrual loss: clinical and quality of life outcomes." Br. J. Obstet. Gynaecol vol. 106, pgs 258-265 (1999). | | | | | | |
| | AO | Mannucci, P.M., "Hemostatic Drugs" New Eng. J. Medicine, vol. 339, (4) pp. 245-253 (1998). | | | | | | |
| | AP | Shaw, R.W., "Assessment of medical treatments for menorrhagia" Br. J. Obstet. Gynaecol, Suppl 11, vol 101, pp. 15-18, (1994). | | | | | | |
| | AQ | Tsementzis, S.A., et al. "Fibrinolytic Activity After Subarachnoid Haemorrhage and the Effects of Tranexamic Acid" Acta Neurochir (Wien) vol 103, pp. 116-121, (1990). | | | | | | |
| | AR | Ylikorkala, O., et al., "Comparison between antifibrinolytic and antiprostaglandin treatment in the reduction of increased menstrual blood loss in women with intrauterine contraceptive devices" Br. J. Obstet. Gynaecol vol. 90, pgs 78-83 (1983). | | | | | | |
| | AS | | | | | | | |
| EXAMINER | | | | | DATE CONSIDERED | | | |
| *EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | | | | | | | | |